These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25168840)

  • 21. [Strengthening the Pan American Network of Official Medicines Control Laboratories].
    Parisi JM; Cairatti D; Castro JL
    Rev Panam Salud Publica; 2016 May; 39(5):255-261. PubMed ID: 27706410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The network of community and national reference laboratories for residues].
    Caroli S
    Ann Ist Super Sanita; 2002; 38(1):69-76. PubMed ID: 12122898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes.
    Milne C; Wagner R; Cano F; Bruysters M; Waeterloos G; Pullirsch D; Wierer M; Mallet L
    NPJ Vaccines; 2023 Feb; 8(1):22. PubMed ID: 36823287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Good manufacturing practice for immunological veterinary medicinal products.
    Todd JI
    Rev Sci Tech; 2007 Apr; 26(1):135-45. PubMed ID: 17633298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Unites States Department of Agriculture Regulation of Veterinary Biological Products. The use of prelicensing evaluation and postlicensing monitoring to achieve regulatory compliance.
    Hill RE; Randall DC
    Qual Assur; 1995 Dec; 4(4):323-8. PubMed ID: 8890360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The challenges of regulating stem cell-based products.
    von Tigerstrom BJ
    Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of user safety, exposure and risk to veterinary medicinal products in the European Union.
    Woodward KN
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):114-28. PubMed ID: 18060673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Registration of new medicinal products in Europe].
    Singer E
    Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FEDESA's point of view: quality, application to IVMPs (immunological veterinary medicinal products).
    Soulebot JP
    Dev Biol Stand; 1992; 79():201-11. PubMed ID: 1286759
    [No Abstract]   [Full Text] [Related]  

  • 36. The evolution of safety assessments for veterinary medicinal products in the European Union.
    Woodward K
    Vet Hum Toxicol; 2004 Aug; 46(4):199-205. PubMed ID: 15303395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International reference preparations for standardization of biological medicinal products.
    Minor P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1145-51. PubMed ID: 25204274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternatives to Animals in the Development and Control of Biological Products for Human and Veterinary Use. Zoological Society, London, UK, 24-26 September 1998.
    Sesardic D; Hendriksen CF
    Biologicals; 1999 Mar; 27(1):55-7. PubMed ID: 10441404
    [No Abstract]   [Full Text] [Related]  

  • 39. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calibration of the human immunoglobulin BRPs for ACA and molecular size (batch 1) and for Fc function and molecular size (batches 1 & 2).
    Sandberg E; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2012 Apr; 2012():1-15. PubMed ID: 23327889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.